Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
Returns on capital
Avalyn Pharma Inc. Common Stock management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
No return metrics data available.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Lyn Baranowski | CEO, President & Director | USD 804.5K | 50 | — | — |
Howard Lazarus | Chief Medical Officer | USD 667.45K | 60 | — | — |
Douglas R. Carlson | CFO & Chief Business Officer | USD 656K | 47 | — | — |
Melissa Rhodes DABT | Chief Operating Officer | USD 635.2K | 48 | — | — |
Jill Denning | Senior Vice President of Clinical Development Operations | — | — | — | — |
Craig Conoscenti | Senior Vice President of Clinical Development | — | — | — | — |
Stephen Pham | Senior Vice President of Product Development | — | — | — | — |
Adam Golden | General Counsel & Head of Business Development | — | 62 | — | — |
James Bishop | Senior Vice President of Business Operations | — | — | — | — |
Cassie Saitow | Senior Director of IR & Corporate Communications | — | — | — | — |
Michelle Patterson | Senior Vice President of Corporate Planning & Portfolio Strategy | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
4
$6.70M
Net Transaction Value
−$6.70M
Net selling
Most Active
FMR LLC
4 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | FMR LLC Indirect | Sell | $164.5K$164,501.40 |
| Nov 10, 26Nov 10, 2026 | FMR LLC Indirect | Sell | $1.5M$1,450,078.92 |
| Nov 9, 26Nov 9, 2026 | FMR LLC Indirect | Sell | $5M$5,046,588.66 |
| Nov 9, 26Nov 9, 2026 | FMR LLC Indirect | Sell | $39.8K$39,835.25 |
Summary
Insiders reported 0 buys worth $0.00 and 4 sells worth $6.70M over the last 12 months. That adds up to net selling of $6.70M. FMR LLC was the most active insider with 4 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
Competitors
Who does Avalyn Pharma Inc. Common Stock compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about AVLN's management, answered from reported figures.
Who manages AVLN?
Avalyn Pharma Inc. Common Stock (AVLN) lists 11 active executives. The top listed executive is Jill Denning, Senior Vice President of Clinical Development Operations.
Are AVLN insiders buying or selling?
Recent insider activity shows net selling of $5.63M.
Continue the stock analysis
Jump to another research area for this company.